Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Johnson & Johnson
SAN DIEGO, June 24, 2014 /PRNewswire/ -- Johnson & Johnson today named Dr. Jennifer Doudna of the University of California at Berkeley and the Howard Hughes Medical Institute, and Dr. Emmanuelle Charpentier, of the Hannover Medical School and Helmholtz Centre for Infection Research (HZI), Germany and The Laboratory for Molecular Infection Medicine Sweden (MIMS), Umea University, Sweden, the winners of the 2014 Dr. Paul Janssen Award for Biomedical Research. Their collaboration led to the discovery of a new method for precisely manipulating genetic information in ways that should produce new insights in health and disease, and may lead to the discovery of new targets for drug development.
"Their discovery of this new DNA editing strategy is considered one of the most significant breakthroughs in molecular biology in the past decade," said Paul Stoffels, MD, Chief Scientific Officer, Johnson & Johnson. "We are pleased to be able to recognize two researchers whose insights, persistence and collaboration have led to a significant leap in our understanding and ability to manipulate genetic processes. The work of Drs. Doudna and Charpentier has the potential to make a significant impact on human health, which is the very heart of Dr. Paul's legacy, as well as our mission at Johnson & Johnson."
The Dr. Paul Janssen Award for Biomedical Research was created by Johnson & Johnson to honor the legacy of one of the most passionate, creative and productive scientists of the 20th century, Dr. Paul Janssen (1926-2003). Dr. Paul – as he was known in the scientific community – founded Janssen Pharmaceutica, which was acquired by Johnson & Johnson in 1961. His work led to the development of more than 80 transformational medicines in several fields, including pain management, psychiatry, infectious disease and gastroenterology.
"The transformational research by Drs. Doudna and Charpentier has uncovered molecular details of an amazing bacterial immunity mechanism. Their findings enable dramatic improvements in the speed, efficiency and flexibility of genome editing," said Dr. Craig Mello, professor of Molecular Medicine, University of Massachusetts Medical School and investigator, Howard Hughes Medical Institute, and chair of the Dr. Paul Janssen Award independent selection committee. "It is widely applicable in biomedical research and its practical applications extend to engineering the genes of plants and animals."
Doudna, Charpentier and their colleagues determined that Cas9 – an enzyme specialized for cutting DNA – can be programmed with single RNA molecules to cleave specific DNA sites, creating a simple and versatile system for genome targeting and editing. This new understanding enables researchers to rapidly model human disease alleles in the laboratory, speeding the search for new drug leads and opening new doors for the treatment of human genetic disorders.
Dr. Doudna is a Howard Hughes Medical Institute Investigator and Li Ka Shing Professor of Biochemistry, Biophysics and Structural Biology, University of California, Berkeley; and Dr. Charpentier is Alexander von Humboldt Professor at Hannover Medical School (MHH), Head of the Department "Regulation in Infection Biology" at the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany, and Guest Professor at The Laboratory for Molecular Infection Medicine Sweden (MIMS) at Umea University.
"I have always focused on basic research, motivated by a desire to understand the world," said Dr. Doudna. "I am very happy about the possibility that this research can lead to something that can be used therapeutically and improve people's health."
"I am pleased to join the list of exceptional past winners of the Dr. Paul Janssen Award for Biomedical Research," said Dr. Charpentier. "I am excited about the potential of our findings to make a real difference in people's lives. The discovery demonstrates the relevance of basic research and how it can transform application in bioengineering and biomedicine."
The winners of the Dr. Paul Janssen Award for Biomedical Research are chosen by an independent selection committee of the world's most renowned scientists. The Award, which includes a $100,000 prize, shared by the two winners, will be presented to Drs. Doudna and Charpentier at ceremonies in the U.S. and Belgium in September.
Drs. Doudna and Charpentier will be honored today at parallel receptions at the 2014 BIO International Convention in San Diego, and The EuroScience Open Forum in Copenhagen. Videos of their acceptance comments can be viewed here: Dr. Charpentier at http://youtu.be/QWspSkFzeMU and Dr. Doudna at http://youtu.be/f9WbVicsX-o.
About The Dr. Paul Janssen Award for Biomedical Research
Dr. Paul Janssen was one of the 20th century's most gifted and passionate researchers. He helped save millions of lives through his contribution to the discovery and development of more than 80 medicines, four of which remain on the World Health Organization's list of essential medicines. The Dr. Paul Janssen Award for Biomedical Research was established by Johnson & Johnson to honor the memory of Dr. Paul. Past winners include Craig Mello, Marc Feldmann, Sir Ravinder Maini, Axel Ullrich, Erik De Clercq, Anthony S. Fauci, Napoleone Ferrara, Victor Ambros, Gary Ruvkun and David Julius. Learn more at www.pauljanssenaward.com.
About the Selection Committee
The Dr. Paul Janssen Award independent selection committee is composed of some of the world's leading scientists, including National Medal of Science winners, Nobel Laureates, members of the National Academy of Sciences and past winners of The Dr. Paul Janssen Award. The 2014 Selection Committee includes:
About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,300 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world. For more information, visit www.jnj.com.
+32 14 60 57 24
Video - http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/ENR/FX-NY55909-20140624-1.mp4
Video - http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/ENR/FX-NY55909-20140624-2.mp4
©2012 PR Newswire. All Rights Reserved.
Can't find what you're looking for?